PRF and platelet concentrates in bone regeneration: adjunct, not replacement — what the evidence actually supports

Platelet concentrates — PRP, PRF, A-PRF, L-PRF and their variants — have been increasingly integrated into regenerative protocols for alveolar and periodontal defects, yet their actual clinical advantage over conventional grafting materials remains a subject of debate. This systematic review addresses a precise question: do platelet-rich preparations provide measurable adjunctive benefits when used in alveolar ridge preservation, periodontal intrabony defect treatment, or implant site development, and how do they compare to established regenerative approaches?

The authors conducted a systematic literature search across major electronic databases, selecting controlled clinical trials and comparative studies evaluating platelet concentrate-based protocols against conventional bone grafts, membranes, or combinations thereof. Outcomes assessed included bone fill, defect resolution, probing depth reduction, clinical attachment level gain, implant survival, and radiographic bone density — covering both periodontal and implant-related surgical contexts.

The findings indicate that platelet concentrates, particularly L-PRF and A-PRF, offer clinically relevant adjunctive benefits when combined with bone substitutes or used alone in contained defects. In periodontal intrabony defects, their use correlates with improved clinical attachment gain and accelerated soft tissue healing. In post-extraction socket preservation, platelet concentrates reduce resorption and support dimensional stability of the ridge, with outcomes comparable or superior to xenografts in several studies. In implant site augmentation, they appear to enhance early vascularization and graft consolidation, though long-term bone volume maintenance shows more variable results across studies.

Comparisons with conventional approaches reveal a pattern of clinical equivalence in many scenarios, with platelet concentrates offering a potential advantage in biological cost: autologous origin, no immunogenic risk, growth factor-mediated acceleration of tissue repair, and reduced need for exogenous biomaterials. However, heterogeneity in preparation protocols, centrifugation parameters, and outcome reporting limits the strength of conclusions.

The clinical take-home message is nuanced but actionable. Platelet concentrates are not a replacement for sound regenerative principles — defect morphology, flap management, and primary closure remain decisive. But as adjuncts, particularly in periodontal osseous defects and alveolar socket management, they offer a biologically rational, clinically supported addition to the regenerative toolkit. For the periodontist and implantologist, their autologous nature and ease of chairside preparation make them a pragmatic choice, especially where minimizing synthetic biomaterials is a clinical or patient-driven priority. Future research should standardize preparation protocols to allow more robust cross-study comparisons.